Evotec SE announced today that there will be two new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating the safety and efficacy of new therapeutic candidates. The research focus is on COVID-19 therapeutics and other viral diseases.
